FDA considers easing peptide restrictions amid wellness trend

The FDA has announced a late‑July advisory meeting to consider allowing compounding pharmacies to produce seven peptides that were previously restricted, and HHS Secretary Robert F. Kennedy Jr. has voiced support for broader access.

The Food and Drug Administration is taking an initial step toward possibly allowing compounding pharmacies to produce seven peptides that the agency had previously restricted. Its Pharmacy Compounding Advisory Committee is scheduled to discuss those peptides at a late‑July meeting. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly supported broader access and said several peptides under review would be removed from a restricted category. The peptides are popular in the wellness market, but many uses and combinations lack rigorous clinical study and public health experts have warned of potential safety gaps. Key developments: - The FDA has scheduled a late‑July advisory meeting to consider whether seven peptides may be appropriate for pharmacy compounding for uses listed in the Federal Register, including ulcerative colitis, wound healing, inflammatory conditions, obesity and insomnia. - The agency also announced a separate advisory meeting to consider five additional peptides by the end of February 2027. - HHS Secretary Robert F. Kennedy Jr. said several peptides would be removed from a restricted category and that restoring regulated access could shift demand away from the black market, according to his social media post. - In 2023 the FDA added more peptides to a category it considers too risky for compounding. - Public health experts and scientists say many peptide uses lack rigorous clinical trials and that safety and efficacy data are limited. - A trade group representing compounding pharmacies said demand from patients and prescribers is pressuring pharmacies and that illicit non‑pharmacy suppliers are active in the gray market. Summary: The advisory meetings mark a formal review that could change which peptides compounding pharmacies are allowed to prepare. Officials who favor broader access argue regulated compounding could reduce gray‑market sales, while scientists and public health experts caution that many peptides lack robust safety and efficacy data. The late‑July meeting and the planned 2027 session are the next scheduled steps.